# US 2025/0367126 A1 · Softgel capsule comprising a h2 receptor antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367126 A1
- Document ID: US20250367126A1
- Status: Published application
- Kind: A1
- Application number: 19/227,824
- Filed: 2025-06-04
- Published: 2025-12-04
- Earliest claimed: 2024-06-04
- Assignees: Kenvue Brands LLC
- Applicants: Kenvue Brands LLC
- Inventors: Bruce P. Smith; Linus G. Fonkwe
- Web page: https://patentgrep.com/patent/US20250367126A1

## CPC

- A61K 9/4858: {Organic compounds}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 31/426: 1,3-Thiazoles
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure generally relates to soft gelatin oral dosage form. In particular the disclosure relates to an oral dosage form comprising a soft gelatin capsule and a liquid fill, where the liquid fill is a suspension of an H2 receptor antagonist in a hydrophobic/lipophilic excipient. The disclosure also relates to a method of treating a gastric disease or disorder by using said oral dosage form.

## Claims

### Claim 1

An oral dosage form comprising a soft gelatin capsule and a liquid fill contained within the soft gelatin capsule,
wherein the liquid fill comprises a suspension of an H2 receptor antagonist in a hydrophobic/lipophilic excipient substantially free from water, and
wherein at least 50%, in wt %, of the hydrophobic/lipophilic excipient consists of linoleic acid or linoleate moiety.

### Claim 2 (depends on 1)

The oral dosage form according to claim 1, wherein the hydrophobic/lipophilic excipient has a HLB value below 3, preferably below 2, preferably at a maximum of 1.

### Claim 3 (depends on 1)

The oral dosage form according to claim 1, wherein the hydrophobic/lipophilic excipient consists of glyceryl monolinoleate, corn oil, or combinations thereof.

### Claim 4 (depends on 1)

The oral dosage form according to claim 1, wherein a solubility of the H2 receptor antagonist in the hydrophobic/lipophilic excipient is below 1 mg/g.

### Claim 5 (depends on 1)

The oral dosage form according to claim 1, wherein the H2 receptor antagonist is selected from the group consisting of cimetidine, ranitidine, nizatidine, roxatidine and famotidine, and pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 5)

The oral dosage form according to claim 5, wherein the H2 receptor antagonist comprises famotidine.

### Claim 7 (depends on 1)

The oral dosage form according to claim 1, wherein the H2 receptor antagonist comprises at least 15%, in wt %, of the liquid fill.

### Claim 8 (depends on 1)

The oral dosage form according to claim 1, wherein the H2 receptor antagonist comprises at least 5 mg per oral dosage form preferably at least 10 mg.

### Claim 9 (depends on 1)

The oral dosage form according to claim 1, wherein after 24 months at least 95% of the H2 receptor antagonist has not degraded.

### Claim 10 (depends on 1)

The oral dosage form according to claim 1, comprising a soft gelatin capsule and a liquid fill contained within the soft gelatin capsule,
wherein the liquid fill consists of a suspension of famotidine in a hydrophobic/lipophilic excipient substantially free from water, and
wherein the hydrophobic/lipophilic excipient consists of glyceryl monolinoleate, corn oil or combinations thereof.

### Claim 11 (depends on 10)

The oral dosage form according to claim 10, comprising a soft gelatin capsule and a liquid fill contained within the soft gelatin capsule,
wherein the liquid fill consists of a suspension of famotidine in a hydrophobic/lipophilic excipient substantially free from water, and
wherein the hydrophobic/lipophilic excipient consists of glyceryl monolinoleate.

### Claim 12 (depends on 10)

The oral dosage form according to claim 10, comprising a soft gelatin capsule and a liquid fill contained within the soft gelatin capsule,
wherein the liquid fill consists of a suspension of famotidine in a hydrophobic/lipophilic excipient substantially free from water, and
wherein the hydrophobic/lipophilic excipient consists of corn oil.

### Claim 13 (depends on 1)

A method of treating a gastric disease or disorder by use of the oral dosage form according to claim 1.
